abstract |
Substituted 2- (azetidin-2-one-1-yl) alkoxyalkylalkanoic acids and 2- (azetidin-2-one-1-yl) arylalkylalkanoic acids, and analogs and derivatives thereof are described. Also described are methods of using the described compounds, and pharmaceutical compositions thereof, to treat conditions that respond to antagonism of one or more vasopressin receptors. [Selection] Figure 1 |